Systemic Bio Named a Top 10 Finalist for the SLAS 2025 Innovation Award
Portfolio Pulse from
Systemic Bio, a subsidiary of 3D Systems (NYSE: DDD), has been named a Top 10 Finalist for the SLAS 2025 Innovation Award. This highlights the potential of their h-VIOS platform in drug discovery using bioprinted tissues.
January 13, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
3D Systems' subsidiary, Systemic Bio, has been recognized as a Top 10 Finalist for the SLAS 2025 Innovation Award, highlighting the potential of their h-VIOS platform in drug discovery.
The recognition of Systemic Bio as a finalist for a prestigious award highlights the innovative capabilities of 3D Systems' subsidiary. This could positively impact investor sentiment and the stock price of 3D Systems in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80